Revvity (RVTY) Total Non-Current Liabilities (2010 - 2026)
Revvity's (RVTY) quarterly Total Non-Current Liabilities came in at $4.0 billion in Q3 2026, down 15.46% on a YoY basis from $4.8 billion in Q3 2025, and down 15.52% quarter-over-quarter from $4.8 billion in Q2 2026.
Analysis
Revvity (RVTY) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Revvity (RVTY) has reported Total Non-Current Liabilities for 17 consecutive years, with $4.0 billion the latest figure, recorded in Q3 2026.
- For the quarter ending Q3 2026, Total Non-Current Liabilities fell 15.46% year-over-year to $4.0 billion; the trailing twelve-month figure through Jul 2026 stood at $4.0 billion (down 15.46% YoY), and the FY2025 full-year result was $4.1 billion, down 12.61% from the prior year.
- Total Non-Current Liabilities fell to $4.0 billion in Q3 2026 per RVTY's latest filing, from $4.8 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $7.8 billion in Q1 2022 and bottomed at $4.0 billion in Q3 2024.
- Historically, Total Non-Current Liabilities has averaged $5.5 billion across 5 years, with a median of $5.5 billion in 2024.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities jumped 84.78% in 2022, then retreated 16.77% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $5.5 billion in 2022, then rose by 2.26% to $5.7 billion in 2023, then retreated by 16.77% to $4.7 billion in 2024, then declined by 12.61% to $4.1 billion in 2025, then retreated by 1.58% to $4.0 billion in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $4.0 billion, $4.8 billion, and $4.1 billion for Q3 2026, Q2 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn | 55.95 Bn |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn | 33.25 Bn |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn | 6.06 Bn |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn | 3.52 Bn |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn | 4.05 Bn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn | 457.16 Mn |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn | 2.88 Bn |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn | 821.06 Mn |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn | 197.96 Mn |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn | 3.06 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 5, 2026 | 4.05 Bn |
| Apr 5, 2026 | 4.79 Bn |
| Dec 28, 2025 | 4.11 Bn |
| Sep 28, 2025 | 4.01 Bn |
| Jun 29, 2025 | 4.79 Bn |
| Mar 30, 2025 | 4.70 Bn |
| Dec 29, 2024 | 4.70 Bn |
| Sep 29, 2024 | 4.00 Bn |
| Jun 30, 2024 | 5.52 Bn |
| Mar 31, 2024 | 5.56 Bn |
| Dec 31, 2023 | 5.65 Bn |
| Oct 1, 2023 | 4.73 Bn |
| Jul 2, 2023 | 6.31 Bn |
| Apr 2, 2023 | 6.56 Bn |
| Jan 1, 2023 | 6.70 Bn |
| Oct 2, 2022 | 5.53 Bn |
| Jul 3, 2022 | 6.97 Bn |
| Apr 3, 2022 | 7.61 Bn |
| Jan 2, 2022 | 7.80 Bn |
| Oct 3, 2021 | 6.43 Bn |